com-www-treatment-37.html
Novo Annual Review 2016
38 / 71
public
com
panies acceleron pharma (nasdaq
: xlrn) is a clinical- stage biotechnology company developing ligand traps that target the endogenous ligands for the tgf superfamily of serine/threonine protein kinase receptors. the company?s lead compound luspatercept is in phase 3 clinical trials for the treatment of anemia associated with myelodysplastic syndrome (mds) and thalassemia. www
.acceleronpharma.com apollo (nasdaq: apen) markets orbera ® and lap- band ® for the treatment of obesity. the company is a leader in flexible endoscopic surgery via overstitch tm and other endoscopic devices. www.apolloendo.com colucid pharmaceuticals (nasdaq: clcd) develops lasmitidan for the treatment of acute migraine. positive phase 3 data has been announced. www.colucid.com corvus pharmaceuticals (nasdaq: crvs) develops drugs that harness the immune system to fight cancer in a new area of medicine known as immuno- oncology. www.corvuspharma.com crispr therapeutics (nasdaq: crsp) is developing transformative gene-based medicines for patients with serious diseases. the therapeutic approach is to cure diseases at the molecular level, using the breakthrough gene editing technology called crispr-cas9. www.crisprtx.com dermira (nasdaq: derm) focuses on the development and commercialisation of novel therapies for the treatment of dermatological conditions. www.dermira.com flexion (nasdaq: flxn) is a specialty pharmaceutical company focused on the development and commercialisation of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (oa) ? a type of degenerative arthritis. www.flexiontherapeutics.com htg molecular diagnostics (nasdaq: htgm) is developing and marketing its edge instrument and assays for quantification of gene expression. they are used for clinical diagnostics and in research. the edge instrument is being launched in the us. www.htgmolecular.com invuity (nasdaq: ivty) is a commercial stage medical technology company pioneering the use of advanced photonics to provide surgeons with improved direct visualisation of surgical cavities during minimally invasive and minimal access surgical procedures. www.invuity.com irhythm technologies (nasdaq: irtc) is a medical device company that develops and markets the zio ® service ? an innovative cardiac monitoring and diagnostic solution, which uses a single-use wearable patch to detect cardiac arrhythmias. www.irhythmtech.com kalvista pharmaceuticals (nasdaq: kalv) develops plasma kallikrein inhibitors for the treatment of diabetic macular oedema. their lead programme is in phase 1 clinical development. www.kalvista.com merus (nasdaq: mrus) is a dutch biotechnology company developing fully human bi-specific antibodies for various oncology treatments. their two lead programmes are for solid tumours and aml. www.merus.nl nabriva therapeutics (nasdaq: nbrv) is focused on the research and development of novel anti- infective agents to treat serious infections. nabriva?s lead product candidate, lefamulin is entering phase 3 clinical trials for the treatment of moderate to severe community-acquired bacterial pneumonia. www.nabriva.com ra pharmaceuticals (nasdaq: rarx) develops drugs for treatment of complement dysregulation diseases. the lead programme is an anti c5 complement inhibitor. www.rapharma.com reata pharmaceuticals (nasdaq: reta) develops new drugs for the treatment of inflammatory diseases and cancer. the lead programmes are in phase 2 clinical development. www.reatapharma.com spectranetics (nasdaq: spnc) develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. www.spectranetics.com verona pharma (lse: vrp) is a clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as copd, asthma and cystic fibrosis. www.veronapharma.com xenon pharmaceuticals (nasdaq: xene) is a genetics-based drug development company. the lead compound is in clinical development for the treatment of pain. www.xenon-pharma.com continued from p. 37 38 novo a/s 2016
acquired-public-initial-39.html
